Close Menu
    Schweiz

    Für den CEO von Novartis sind die Arzneimittelpreise in der Schweiz zu niedrig.


    Was denkst du über diesen Nachrichtenartikel aus dem RTS (Artikel auf Französisch)?

    https://www.rts.ch/info/economie/2025/article/les-prix-des-medicaments-en-suisse-sont-trop-bas-estime-le-patron-de-novartis-29004298.html

    "Novartis zielt darauf ab, die Preislücke von Medikamenten zwischen den Vereinigten Staaten und anderen Industrieländern zu beseitigen. Der CEO der in Basel ansässigen Pharmagruppe Vas Narasimhan ist der Ansicht, dass Länder außerhalb der USA die Pflicht haben, mehr zur Innovation beizutragen, und der Ansicht, dass die Preise in der Schweiz zu niedrig sind."

    For the CEO of Novartis, drug prices in Switzerland are too low.
    byu/JonHaf inSwitzerland



    Von JonHaf

    Share.
    View 23 Comments

    23 Kommentare

    1. Gnurx on

      He’s totally correct. 

      After I pay my health insurance, I still have some money for rent left. 

    3. cryingInSwiss on

      where the FUCK are the politicians

      yes yes I know lobbyism
      But how is it even possible that we don’t have even one politician with a conscience

    4. rainbow4enby on

      Perfect timing for the yearly KVG price shock… but SVP still thinks Trump is better for their country than the EU and a great and brilliant leader…

    5. Unusual-Context8482 on

      I think the interest rates on the CEO’s loans are too low.
      He clearly can afford more.

    8. cheapcheap1 on

      And here we see why CEO salaries are so high: You couldn’t torture me into saying shit like that in Guantanamo.

    9. AutomaticAccount6832 on

      Let’s make a deal with big pharma. They can raise the prices as much as they want as long they pay double of it as additional taxes. So they can show the US how normal their prices are.

    10. wantonio2w on

      if they start raising prices, someone should petition the federal government to invalidate their patents and allow other enterprises to produce these pharmaceuticals. then we’ll see whether they still want to increase prices.

    11. Turicus on

      Lots of uninformed comments. In Switzerland, neither Novartis, nor its CEO can decide this. Prices are regulated by BAG.

    13. Basspayer on

      If he wants more contributions to innovation, he can start by reducing his 20 million salary

    14. Linkario86 on

      So are everyone’s salaries, except for top execs who get packages way beyond of what they deserve.

    19. halo_skydiver on

      First, as an ex McKinsey he needs to feed the monster. 2nd, his wife is the CEO of Idorsia in Switzerland, so between them they probably couldn’t give a crap about higher prices, as long as the bonus and pay package are stable.

    20. piecesofapuzzle on

      The prices of drugs in Switzerland are relatively low when taking income into account.

    21. askswitzerland on

      Wasn’t that a retorical reply to Trump after he asked for lower drug prices in the US?

    22. Fadjaros on

      The Man wants a raise! Poverty line is approaching fast

      In 2024, Novartis CEO Vas Narasimhan’s total compensation reached CHF 19.2 million.

      2018: When Vas Narasimhan first became CEO, his compensation was around CHF 10 million.

      2023: His pay almost doubled from the previous year, reaching CHF 16.2 million ($18.8 million), due to meeting set bonus targets.

    Leave A Reply